Product image of Olmesartan Medoxomilo + Hidroclorotiazida Fantex (Olmesartan Medoxomil, Hydrochlorothiazide) supplied by GNH India

Olmesartan Medoxomilo + Hidroclorotiazida Fantex

Active Ingredient:
Olmesartan Medoxomil, Hydrochlorothiazide
Origin:
EU

Olmesartan Medoxomilo + Hidroclorotiazida Fantex (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Fantex, is an angiotensin II receptor blocker presented as a tablet for oral use. It is combined with hydrochlorothiazide, a thiazide‑type diuretic, to help lower blood pressure in adults with hypertension.

GNH India supplies Olmesartan Medoxomilo + Hidroclorotiazida Fantex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Pentafarma - Sociedade Tecnico-Medicinal S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan Medoxomil combined with hydrochlorothiazide is used in the management of hypertension, acting on the renin‑angiotensin‑aldosterone system to reduce elevated blood pressure.

  • Hypertension: improves blood pressure control when monotherapy is insufficient.
  • Diastolic hypertension: lowers diastolic pressure to target levels.
  • Resistant hypertension: provides additional diuretic effect to achieve therapeutic goals.
  • Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction in hypertensive patients.
  • Edema associated with hypertension: reduces fluid retention through the diuretic component.

How It Works

  • Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis. The combined actions decrease peripheral vascular resistance and plasma volume, resulting in lowered systemic blood pressure.

Side Effects

Olmesartan Medoxomilo + Hidroclorotiazida Fantex may cause a range of adverse reactions.

Common Side Effects

  • Dizziness or light‑headedness.
  • Headache.
  • Fatigue.
  • Increased urination.
  • Electrolyte disturbances (e.g., low potassium).
  • Mild gastrointestinal discomfort.

Serious or Rare Side Effects

  • Severe hypotension.
  • Acute kidney injury.
  • Hyperkalemia or severe electrolyte imbalance.
  • Angio‑edema involving face, lips or tongue.
  • Liver enzyme elevation.
  • Blood dyscrasias such as neutropenia.

Precautions & Warnings

When prescribing Olmesartan Medoxomilo + Hidroclorotiazida Fantex, clinicians should consider several safety aspects.

  • Renal function: assess baseline creatinine and monitor periodically.
  • Electrolytes: check serum potassium and sodium levels, especially with diuretic use.
  • Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
  • Concomitant potassium‑sparing agents: monitor for hyperkalemia.
  • Hypotension risk: caution in patients with volume depletion or on other antihypertensives.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan Medoxomilo + Hidroclorotiazida Fantex interacts with several medicines that can modify its efficacy or safety.

Major Interactions (Avoid)

  • Aliskiren combined with an ARB in diabetic patients – increased risk of renal impairment.
  • Potassium supplements or potassium‑sparing diuretics – risk of hyperkalemia.
  • Lithium – may increase lithium serum concentrations.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may reduce antihypertensive effect and affect renal function.
  • Cyclosporine or tacrolimus – can increase serum levels of olmesartan.
  • Antidiabetic agents – may enhance glucose‑lowering effect, requiring dose adjustment.

Frequently Asked Questions

Olmesartan Medoxomilo + Hidroclorotiazida Fantex is a fixed‑dose combination of an angiotensin II receptor blocker and a thiazide diuretic that is prescribed to lower elevated blood pressure in adults with hypertension, including cases where additional diuretic effect is needed to reach target levels.

Olmesartan medoxil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide reduces sodium and water reabsorption in the kidney, increasing urine output. Together they lower vascular resistance and plasma volume, resulting in reduced systemic blood pressure.

The appropriate dose of Olmesartan Medoxomilo + Hidroclorotiazida Fantet is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and response to therapy. Dosage adjustments are made according to clinical guidelines and individual patient needs.

Olmesartan Medoxil is contraindicated in pregnancy, particularly in the second and third trimesters, because it can harm the developing fetus. Breastfeeding is not recommended as the drug may be excreted in milk. Alternative antihypertensive agents should be considered for pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy using an ARB or a thiazide alone, the Olmesartan‑hydrochlorothiazide combo offers dual mechanisms that often achieve better blood‑pressure control with a single tablet, reducing pill burden. It is generally comparable to other ARB‑diuretic combinations but may differ in potency, dosing flexibility and side‑effect profile.

Store the tablets at ambient temperature, below 25 °C, in the original container. Protect them from moisture, excessive heat and direct sunlight to maintain stability and potency.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional. Swallow the tablet whole with a glass of water and do not split or crush it unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, hyperkalemia, and angio‑edema. Patients should be monitored for sudden drops in blood pressure, changes in renal function, electrolyte disturbances, and any signs of swelling in the face, lips or throat.

Individuals with known hypersensitivity to olmesartan, hydrochlorothiazide or any component of the formulation should avoid it. It is also contraindicated in pregnant women (second and third trimesters), patients with severe renal impairment, and those taking potassium‑sparing agents without careful monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT